Abstract

To analyze the clinical efficacy and assess the safety of karelizumab combined with apatinib in the treatment of intermediate and advanced hepatocellular carcinoma. Forty-four patients diagnosed with intermediate and advanced hepatic malignant tumors in our hospital were retrospectively collected from January 2019 to June 2020, and the patients were divided into karelizumab combined with abatinib group A (22 patients) and abatacept group B (22 patients) according to the different treatment methods. Baseline data, clinical outcomes after 1 mo, 3 mo and 6 mo of follow-up were compared between the two groups. The follow-up period was up to December 31, 2022 and patients were counted for progression-free overall survival, and progression-free survival. Treatment-related adverse events were assessed using the common terminology criteria for adverse events. Risk factors affecting progression-free survival were analyzed using univariate and multivariate analysis with Cox risk regression model. Treatment-related adverse events were assessed using the common terminology criteria for adverse events. The best outcome of each patient was recorded; complete response, partial response, stable disease and progressive disease at the best outcome were 9 (20.45), 20 (45.45 %), 7 (15.91 %) and 8 (18.18 %), respectively. The objective remission rate of karelizumab combined with apatinib in the treatment of intermediate and advanced hepatocellular carcinoma is high and the safety is good, which lays the foundation for the subsequent clinical trials to be carried out.